Nuvectis Pharma Announced 33% Response Rate And 100% Disease Control Rate Observed In Patients Evaluated For Efficacy From The NXP800 Phase 1b Clinical Trial In Platinum-Resistant ARID1a-Mutated Ovarian Cancer
Nuvectis Pharma 宣布,对铂耐药 ARID1A 突变卵巢癌的 NXP800 1b 期临床试验疗效进行评估的患者中,观察到的反应率为 33%,疾病控制率为 100%